ARE-770

Aristea Therapeutics was a clinical-stage immunology focused biopharmaceutical company that specialized in developing novel therapies for serious inflammatory diseases. The company's lead program, RIST4721 (also known as ARE-770 during early development or in specific contexts), was a potent and selective small molecule CXCR2 antagonist designed to treat orphan inflammatory conditions such as palmoplantar pustulosis. Despite advancing its lead candidate into Phase 2 clinical trials and securing significant Series B funding, the company announced its closure in early 2023 due to safety signals observed in clinical trials. Aristea was headquartered in San Diego and was built on assets originally spun out from AstraZeneca.